Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2.
Caguana-Vélez OA, Khilzi K, Piccari L, Rodríguez-Sevilla JJ, Badenes-Bonet D, Gonzalez-Garcia J, Chalela R, Arita M, Rodó-Pin A, Herranz A, Admetlló M, Villar-Garcia J, Molina L, Zuccarino F, Gea J, Balcells E, Rodríguez-Chiaradia DA. Caguana-Vélez OA, et al. Among authors: herranz a. Respiration. 2024;103(2):79-87. doi: 10.1159/000536064. Epub 2024 Feb 7. Respiration. 2024. PMID: 38325355
Intra-amniotic infection and/or inflammation is associated with fetal cardiac concentric hypertrophy and diastolic dysfunction in preterm labor and preterm prelabor rupture of membranes.
Murillo C, Rueda C, Larroya M, Boada D, Grau L, Ponce J, Herranz A, Gómez O, Ferrero S, Andreu-Fernández V, Gratacós E, Crispi F, Palacio M, Cobo T. Murillo C, et al. Among authors: herranz a. Am J Obstet Gynecol. 2024 Jan 9:S0002-9378(23)00747-0. doi: 10.1016/j.ajog.2023.10.017. Online ahead of print. Am J Obstet Gynecol. 2024. PMID: 38290925
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Ramos-Ruperez E, Escudero-Vilaplana V, Ruiz-Briones P, Collado-Borrell R, Villanueva-Bueno C, Revuelta-Herrero JL, González-Haba E, Garcia-Gonzalez X, Ibañez-Garcia S, Perez-Ramirez S, Zatarain-Nicolás E, Herranz A, Sanjurjo M. Ramos-Ruperez E, et al. Among authors: herranz a. Front Oncol. 2023 Aug 25;13:1220305. doi: 10.3389/fonc.2023.1220305. eCollection 2023. Front Oncol. 2023. PMID: 37692846 Free PMC article.
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.
Chiriboga CA, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, Kostera-Pruszczyk A, Jaber B, Gorni K, Kletzl H, Carruthers I, Martin C, Warren F, Scalco RS, Wagner KR, Muntoni F; JEWELFISH Study Group. Chiriboga CA, et al. Neurol Ther. 2023 Oct;12(5):1799-1801. doi: 10.1007/s40120-023-00503-7. Neurol Ther. 2023. PMID: 37395990 Free PMC article. No abstract available.
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.
Chiriboga CA, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, Kostera-Pruszczyk A, Jaber B, Gorni K, Kletzl H, Carruthers I, Martin C, Warren F, Scalco RS, Wagner KR, Muntoni F; JEWELFISH Study Group. Chiriboga CA, et al. Neurol Ther. 2023 Apr;12(2):543-557. doi: 10.1007/s40120-023-00444-1. Epub 2023 Feb 13. Neurol Ther. 2023. PMID: 36780114 Free PMC article.
Possible heart failure caused by osimertinib in a lung cancer patient.
Ruiz-Briones P, Escudero-Vilaplana V, Collado-Borrell R, Vicente-Valor J, Alvarez R, Villanueva-Bueno C, Narrillos-Moraza Á, Herranz A, Sanjurjo M. Ruiz-Briones P, et al. Among authors: herranz a. J Oncol Pharm Pract. 2023 Jun;29(4):1015-1020. doi: 10.1177/10781552221143787. Epub 2022 Dec 8. J Oncol Pharm Pract. 2023. PMID: 36480925
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.
Romero-Jimenez R, Escudero-Vilaplana V, Chamorro-de-Vega E, Ais-Larisgoitia A, Lobato-Matilla E, Somoza-Fernández B, Ruiz-Briones P, González C, Baniandrés O, Menchén L, Lobo-Rodríguez C, Herranz A, Sanjurjo M. Romero-Jimenez R, et al. Among authors: herranz a. Front Immunol. 2022 Jul 28;13:915578. doi: 10.3389/fimmu.2022.915578. eCollection 2022. Front Immunol. 2022. PMID: 35967330 Free PMC article.
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App.
Escudero-Vilaplana V, Romero-Medrano L, Villanueva-Bueno C, Rodríguez de Diago M, Yánez-Montesdeoca A, Collado-Borrell R, Campaña-Montes JJ, Marzal-Alfaro B, Revuelta-Herrero JL, Calles A, Galera M, Álvarez R, Herranz A, Sanjurjo M, Artés-Rodríguez A. Escudero-Vilaplana V, et al. Among authors: herranz a. Front Oncol. 2022 Jul 13;12:880430. doi: 10.3389/fonc.2022.880430. eCollection 2022. Front Oncol. 2022. PMID: 35936756 Free PMC article.
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.
Escudero-Vilaplana V, Collado-Borrell R, Gómez Martínez-Sagrera P, Villanueva-Bueno C, Revuelta-Herrero JL, Gonzalez-Haba E, Hoyo-Muñoz Á, Jerez Gilarranz Y, Marzal-Alfaro B, Herranz A, Martin M, Sanjurjo M. Escudero-Vilaplana V, et al. Among authors: herranz a. J Cancer Res Clin Oncol. 2023 Jul;149(7):2855-2882. doi: 10.1007/s00432-022-04172-1. Epub 2022 Jul 6. J Cancer Res Clin Oncol. 2023. PMID: 35790560
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.
García-Sánchez S, Collado-Borrell R, González-Haba E, Revuelta-Herrero JL, Escudero-Vilaplana V, Marzal-Alfaro MB, Sánchez-Fresneda MN, Mur-Mur A, Herranz A, Martín M, Sanjurjo M. García-Sánchez S, et al. Among authors: herranz a. Front Oncol. 2022 Jun 8;12:889575. doi: 10.3389/fonc.2022.889575. eCollection 2022. Front Oncol. 2022. PMID: 35756684 Free PMC article.
122 results